Orchestrating the immune Response
TO Defeat Cancer & Infectious Diseases

Engineering precision immunity

Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer and infectious diseases with potent lymph node targeted immunotherapies and vaccines. Elicio’s Amphiphile platform combines expertise in materials science and immunology  to develop novel immunotherapies and vaccines, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.

»LEARN MORE

Lymph nodes:
where the immune response is orchestrated


Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in early 2021.

» LEARN MORE

 

 

NEXT-GENERATION IMMUNO-ONCOLOGY PLATFORM

Our programs

Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2021. This program consists of an Amphiphile vaccine combined with Elicio’s universal AMP CpG adjuvant (ELI-004) with the potential to elicit powerful immune responses against the seven key KRAS mutations, found in 25% of all solid tumors, including 90% of pancreatic cancers, and 40% of colorectal cancers.

»LEARN MORE

»VIEW OUR PIPELINE

Latest News

Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002– A Therapeutic Vaccine Targeting mutated KRAS Cancers
CAMBRIDGE MA., February 23, 2021 – Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph-node targeting Amphiphile technology, announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for ELI-002. ELI-002 is an Amphiphile (AMP) KRAS therapeutic vaccine containing AMP mKRAS peptides and a proprietary AMP CpG adjuvant, administered subcutaneously. » Read more
Elicio Therapeutics Secures a Total of $73 Million in Series B Financing
CAMBRIDGE MA., February 17, 2021 – Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, announced the successful completion of Series B financing bringing the total funds raised in the current round to $73 million. Elicio funding has been established from an international investor base, including multiple strategic and institutional investors » Read more

Orchestrating the immune system for precision immunity — Download this article to see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.

A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2 Download this presentation